Navidea Biopharmaceuticals, Inc. (NASDAQ:NAVB) was founded in 1983, formerly known as Neoprobe Corporation, and changed to its current name in January 2012. It is headquartered in Dublin, Ohio, and has 19 full-time employees. It is a biopharmaceutical company with a focus on For the development and commercialization of precise immunodiagnostics and immunotherapeutics.
Navidea Biopharmaceuticals, Inc. (NAVB):
Navidea Biopharmaceuticals is a leader in precision medicine. Its products have immuno-targeted products designed to help identify the locations and pathways of undetected diseases, improve diagnosis accuracy, clinical decision-making, targeted treatment, and patient care.
Navidea Biopharmaceuticals applies the company’s Manocept™ technology, Navidea is committed to developing next-generation targeted diagnosis and treatment for cancer, autoimmune diseases and other inflammatory diseases.
Navidea Biopharmaceuticals is divided into two departments to operate : Diagnostic Substances and Therapeutic Development Programs.
Navidea Biopharmaceuticals has developed:
- Manocept platform to target and activate the CD206 mannose receptor expressed on macrophages.
- NAV4694, a fluorine-18 labeled positron emission tomography imaging agent, is used to assist in imaging and evaluating patients with signs or symptoms of Alzheimer’s disease and mild cognitive impairment.
- The company is also developing NAV5001, an iodine-123-labeled single-photon emission computed tomography imaging agent for the diagnosis of Parkinson’s disease and other movement disorders, and may be used as a diagnostic aid for dementia.
- Diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and treatment development plans, such as the treatment application of its Manocept platform, and various development plans.